 SERA sells PreTRM, a CLIA-lab based assay to determine the risk of a woman having a pre-term birth a birth prior to 37 weeks of gestation. After IPOing in July 2021 at 16, the Company has since lost over 80 of its value and trades at 50 of its cash and marketable securities. 